Passage Bio (NASDAQ:PASG) Director Athena Countouriotis purchased 10,000 shares of the stock in a transaction dated Tuesday, March 24th. The stock was acquired at an average cost of $14.74 per share, for a total transaction of $147,400.00.
PASG traded up $0.72 during trading on Wednesday, reaching $14.74. 161,099 shares of the company were exchanged, compared to its average volume of 373,389. Passage Bio has a 12-month low of $8.09 and a 12-month high of $23.25.
PASG has been the subject of several analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Passage Bio in a report on Tuesday. They issued an “overweight” rating and a $25.00 price objective for the company. Chardan Capital assumed coverage on shares of Passage Bio in a research note on Wednesday. They issued a “buy” rating and a $30.00 price objective for the company. Cowen assumed coverage on Passage Bio in a research report on Tuesday. They set an “outperform” rating on the stock. Finally, Goldman Sachs Group began coverage on Passage Bio in a research report on Tuesday. They set a “buy” rating and a $27.00 target price on the stock.
Passage Bio, Inc, a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has a research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Featured Story: Purposes and Functions of the Federal Reserve
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.